Hello, visitor!

Article:
Making Healthcare More Accessible in Asia. Zuellig Pharma provides world-class pharmaceutical distribution, digital and commercial services to support the evolving healthcare needs in the region. Unlock the potential of Asia with Zuellig Pharma's unique healthcare solutions.


Click here for login date in asia




Australia Brunei Cambodia China Hong Kong & Macau India Indonesia Japan Korea Malaysia Myanmar Philippines Singapore Taiwan Thailand Vietnam. Zuellig Pharma's depot in South Australia is a TGA-licensed facility that is approximately 1,300 sq.m. The facility has managed over 1,000 clinical trials since its foundation and currently manages more than 350 clinical trials. Opportunities. Clinical Trial Supplies Market to reach USD 5.7B by 2027. Healthcare CROs market in Australia and New Zealand valued at USD 1B in 2022. CAGR of 11.5% expected for healthcare CROs market from 2023-2030. Virtual clinical trials adoption to drive CRO industry growth in the region. Clinical trials in Australia offer R&D tax advantages and cost efficiency, driving industry growth. Capabilities. Global depot & cold chain logistics for reliable healthcare delivery. Sophisticated temperature-controlled. infrastructure adhering to industry standards (GDP, GMP, CSV, HSE). Smart Sourcing Solution for unparalleled access to medicine, incl. controlled drugs. Specialised cold chain for temperature-sensitive materials. Innovative patient-centric approach to clinical trials with depot-to-patient solutions. Zuellig Pharma has a Brunei warehouse facility with an area of 7,330 sq.m. and a 225-pallet capacity for pharmaceutical, consumer, and medical device and diagnostics products. We serve over 90 healthcare customers nationwide, providing 100% coverage from government and private hospitals, specialist clinics, and chain pharmacies. Our certifications in Brunei for GDP, GDSP, and ISO 9001 (2015) ensure world-standard quality management system. Brunei's economic characteristics present immense business and tender opportunities, with a GDP of BND 5.8B as of Q3 2022 and 0.9% year-over-year growth, with a population size of approximately 450,000 as of 2022. Opportunities. Brunei's government tenders make up 70% of healthcare business. Thriving retail business with potential for chain pharmacy expansion. Growing oncology opportunities in public and private sectors. Potential for Brunei's Ministry to plan, promote, and develop medical tourism. Increasing demand for health and medical services due to ageing population. Capabilities. Leading healthcare provider in Brunei with 36 years of experience as only foreign invested company. Largest distributor and market leader, serving 9 of top 10 pharma clients in Brunei. Excellent RA capabilities, holding market authorisation for 25% of registered medicinal products with MOH. Innovative, automated warehouse system handles 80% of biologics and cold chain products in Brunei. Robust tender management team with excellent track record in handling MOH tenders at scale. Zuellig Pharma's Cambodia facilities offer a newly-built distribution centre with an over 6,300 sq.m. warehouse and 1,200 sq.m. mezzanine for healthcare products, including 6,400 pallets in 6-high racking and 240 cold room storage pallets. With 90% coverage of ethical, pharmacy, and modern trade, we serve over 10,000 healthcare customers nationwide, including hospitals, clinics, and pharmacies, through 200 sales and marketing representatives. Our quality of work is recognised with certifications such as GDSP, GMP, GDPMDD, and ISO 9001:2015. Opportunities. Expansion of universal healthcare boosts medical services utilisation. NGOs continue to provide essential medicines. Basic medicines are vital due to regional production and low domestic manufacturing. Total pharmaceutical sales reached USD 386M in 2022 with per capita spending at USD 23. Pharmaceutical consumption rises to treat growing prevalence of chronic lifestyle diseases. Capabilities. Zuellig Pharma has 20 years' experience as healthcare provider in Cambodia, serving four top 10 Pharma clients. Largest cold-room facility in Cambodia with state-of-the-art infrastructure for healthcare. Proven cold chain tech maintains optimal quality during delivery. Passive packaging with unique thermal isolation chamber system. Patient-centric affordability and adherence programs. Custom mobile app for client program admin, enrolments, and updates. Zuellig Pharma China's Beijing facility, with 20 years of clinical supply experience, is GDP/GMP compliant and a trusted partner for various clients in clinical trials, including pharmaceutical companies, CROs, CMOs, biopharmaceutical firms, medical device companies, and diagnostic firms. Opportunities. China's pharmaceutical market to reach USD 161.8B by 2023, accounting for 30% of global market. Ageing population and increased life expectancy driving rising demand for healthcare in China. Pharma sales in China projected to grow by 4.04% in 2022 and 3.58% in 2023. Chinese government promoting industry consolidation to regulate and control drug pricing. China imports biotechnology pharmaceuticals to meet growing domestic demand. Capabilities. Reliable global cold chain logistics network Sophisticated GDSP and GMP temperature-controlled facilities Smart sourcing solution for unparalleled medicine access Specialised cold chain solutions for sensitive materials in clinical storage Central distribution service for global studies Tailored repackaging services with multilingual labels. Zuellig Pharma has two warehouses in Hong Kong spanning over 48,000 sq.m., offering air-conditioned storage for 24,000 pallets and cold chain storage for 800 pallets. We serve 10,000+ healthcare customers, including hospitals, clinics, dentists, and drug stores. Zuellig Pharma moves 48,000 cubic meters of products annually and has won awards such as the HR Distinction Awards - Excellence in Employee Wellbeing and Occupational Health Award - Excellence Award of Joyful@Healthy Workplace Best Practices Award. Opportunities. Opportunities in China GBA for Hong Kong drugs and medical devices in public hospitals Predicted 3.5%-5.5% economic growth for Hong Kong in 2023 High life expectancy in Hong Kong due to advanced healthcare and health consciousness Aging population driving demand for healthcare services and products Increased demand for consumer health post-COVID-19 due to raised health consciousness Smart hospitals and tele-health offer innovative and sustainable solutions for growing service demand. Capabilities. Over 40 years healthcare experience in Hong Kong Expert in healthcare solutions from storage to delivery Specialised in cold chain storage and distribution with certified facilities Over 20 years of vaccine and vaccination program experience Strong relationships with top healthcare companies in Hong Kong & Macau DoH approved and GMP certified secondary repackaging facilities. Zuellig Pharma's facility in India is strategically-located in Mumbai to ensure that products and services are made available with the shortest leadtime. Covering over 1,530 sq.m., the facility offers one-stop solutions for every client's clinical trial needs, including a global depot and cold chain logistics network with temperature-controlled infrastructure and GDSP and GMP facilities for fast product and service availability. India is a cost-efficient and profitable market for major pharma, and biotech companies, as well as CROs, with local models meeting country standards. Opportunities. Clinical trial industry in India to grow at 8.2% per annum until 2030. Consistent patient population and easy access to modern medical technology in India. India offers a favorable currency exchange rate for pharma and biotech companies.













Dateinasia sign in


Truly asian dating login


Login date in asia


Dateinasia sign up